• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Purification of cell culture-derived influenza A virus via continuous anion exchange chromatography on monoliths

tetano

Editor, Senior Moderator
Vaccine. 2017 Jul 17. pii: S0264-410X(17)30894-0. doi: 10.1016/j.vaccine.2017.06.086. [Epub ahead of print]
[h=1]Purification of cell culture-derived influenza A virus via continuous anion exchange chromatography on monoliths.[/h] Fischer LM[SUP]1[/SUP], Wolff MW[SUP]2[/SUP], Reichl U[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The continuously increasing demand for potent and safe vaccines and the intensifying economic pressure on health care systems underlines the need for further optimization of vaccine manufacturing. Here, we focus on downstream processing of human influenza vaccines, investigating the purification of serum-free cell culture-derived influenza virus (A/PR/8/34 H1N1) using continuous chromatography. Therefore, quaternary amine anion exchange monoliths (CIM? QA) were characterized for their capacity to capture virus particles from animal cells cultivated in different media and their ability to separate virions from contaminating host cell proteins and DNA. The continuous chromatography was implemented as simulated moving bed chromatography (SMB) in a three zone open loop configuration with a detached high salt zone for regeneration. SMBs exploiting 10% and 50% of the monoliths' dynamic binding capacity, respectively, allowed the depletion of >98% of the DNA and >52% of the total protein. Based on the hemagglutination assay (HA assay), the virus yield was higher at 10% capacity use (89% vs. 45%). Both SMB separations resulted in a ratio of total protein to hemagglutinin antigen (based on single radial diffusion assay, SRID assay) below the required levels for manufacturing of human vaccines (less than 100?g of protein per virus strain per dose). The level of contaminating DNA was five-times lower for the 10% loading, but still exceeded the required limit for human vaccines. A subsequent Benzonase? treatment step, however, reduced the DNA contamination below 10ng per dose. Coupled to continuous cultivations for virus propagation, the establishment of integrated processes for fully continuous production of vaccines seems to be feasible.
Copyright ? 2017 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Anion exchange chromatography; Continuous chromatography (simulated moving bed); Downstream processing; Influenza virus; Monolith; Vaccine purification

PMID: 28729020 DOI: 10.1016/j.vaccine.2017.06.086
 
Back
Top Bottom